In 2017 the Precision-Panc Platform was founded, bringing together expertise in pancreatic cancer from the University of Glasgow, CRUK Beatson Institute, CRUK Cambridge Institute, CRUK Manchester Institute, the Institute of Cancer Research in London, the University of Oxford and the NHS.

With 10,000 patients diagnosed annually in the UK with pancreatic cancer (330,000 worldwide) and 9,300 deaths a year, by 2025 pancreatic cancer is predicted to be the second most lethal cancer after lung cancer. Pancreatic cancer is a very complex cancer with little in the way of effective treatments.

There is now a UK wide network of over 30 hospitals that can offer precision medicine clinical trials to patients with pancreatic cancer.

Precision medicine clinical trials, based in the genomics of the patient and their tumour, offers hope for the 85% of pancreatic cancer patients who are not eligible for surgery

In Precision-Panc all registered patients have their genome testing using Glasgow Precision Oncology Laboratories bespoke panel.

There is excellent evidence that participation in clinical trials is associated with better outcomes for patients. Networked clinical trials with researchers across the country share expertise and knowledge, as well as creating and sharing infrastructure, leading to trials which are quicker to set up and recruit.

At Precision-Panc the focus is on the patient, and we work closely with a Patient Advisory Group organised through Pancreatic Cancer UK and Cancer Research UK.

Precision-Panc also enjoys broad stakeholder support from pancreatic cancer charities, patient organisations and industry partners